Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

University Hospital, Ghent60 enrolled

Overview

Patients will be randomized into two groups (1/1) during one year: * 40 mg adalimumab subcutaneously (sc) every other week * placebo The effect on x-rays and clinical parameters will be evaluated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Erosive Osteo-Arthritis

Interventions

Adalimumab (40 mg sc every other week)DRUG

Adalimumab (40 mg sc every other week)

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clear erosive image on x-ray of at least one interphalangeal finger joint

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

Evaluation of x-rays

Evaluation of clinical parameters (pain, daily functioning, etc.)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.